Direct evidence for a role of glutamate in the expression of the opioid withdrawal syndrome
The DOI matches its Crossref record; 37 of the 39 references it cites were found in a registry or an index.
Abstract
To investigate the role of glutamate in the expression of the withdrawal signs from opioids, rats were intracerebroventricularly (i.c.v.) infused continuously with morphine (a mu-opioid receptor agonist, 26 nmol/microliters per h) or butorphanol (a mixed mu/delta/kappa-opioid receptor agonist, 26 nmol/microliters per h) through osmotic minipumps for 3 days. An i.c.v. injection of glutamate (5 and 50 nmol/5 microliters) dose dependently induced withdrawal signs in morphine- or butorphanol-dependent animals. The withdrawal signs precipitated by the glutamate injection were comparable to those precipitated by an opioid receptor antagonist, naloxone (48 nmol/5 microliters), except for the expression of some specific behaviors and the duration of withdrawal signs. Glutamate or naloxone challenge failed to precipitate any withdrawal signs in saline controlled animals. On the other hand, the expression of the withdrawal signs precipitated by glutamate or naloxone in opioid-dependent animals was completely blocked by pretreatment with MK-801 [a NMDA receptor antagonist, (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cycloheptan-5,10-imine], 0.1 mg/kg, i.p. These unique actions of glutamate in continuously opioid-infused rats suggest that a rapid central release of glutamate may be a key factor in the expression of withdrawal signs from opioids. Furthermore, this effect may be mediated by the NMDA subtype of glutamate receptors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For opioids, the noncompetitive glutamate receptor antagonist MK-801 blocked the expression of withdrawal signs that were precipitated by naloxone in opioid-dependent animals (Tanganelli et al., 1991;Tokuyama et al., 1996), suggesting a hyperglutamatergic contribution to opioid withdrawal.”
From Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development (2021) · cites this paper as Tokuyama et al., 1996
Citations
Cites
The Rat Brain in Stereotaxic Coordinates
(1982) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 51,963
Glycine potentiates the NMDA response in cultured mouse brain neurons
Johnson, J. W., & Ascher, P. (1987) · Nature · doi:10.1038/325529a0 · Cited by 3,139
Inhibition of Morphine Tolerance and Dependence by the NMDA Receptor Antagonist MK-801
Trujillo, K. A., & Akil, H. (1991) · Science · doi:10.1126/science.1824728 · Cited by 1,210
Quinoxalinediones: Potent Competitive Non-NMDA Glutamate Receptor Antagonists
Honoré, T., Davies, S. N., Drejer, J., Fletcher, E. J., Jacobsen, P., Lodge, D., & Nielsen, F. E. (1988) · Science · doi:10.1126/science.2899909 · Cited by 1,191
Watkins, J. C., Korgsgaard-Larsen, P., & Honoré, T. (1990) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(90)90038-a · Cited by 901
AGHAJANIAN, G. K. (1978) · Nature · doi:10.1038/276186a0 · Cited by 802
Metabotropic glutamate receptors in brain function and pathology
Schoepp, D. D., & Conn, P. J. (1993) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(93)90107-u · Cited by 791
Martin, W. R. (1983) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06637-2 · Cited by 648
Multiple opioid receptors: ligand selectivity profiles and binding site signatures.
Goldstein, A., & Naidu, A. (1989) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09190-4 · Cited by 445
[3H]U-69593 a highly selective ligand for the opioid κ receptor
Lahti, R. A., Mickelson, M. M., McCall, J. M., & Von Voigtlander, P. F. (1985) · European Journal of Pharmacology · doi:10.1016/0014-2999(85)90431-5 · Cited by 444
Research works printed but not linked: 1
- Feng, 1994, Opioid receptor subtypes modurate pontine excitatory amino acid (EAA) levels differently in butorphanol and morphine dependence, Soc. Neurosci. Abstr., 20, 1232
Cited by
Glutamatergic substrates of drug addiction and alcoholism
Gass, J. T., & Olive, M. F. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.06.039 · Cited by 484
Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development
Koob, G. F. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000083 · Cited by 337
NMDA and opioid receptors: their interactions in antinociception, tolerance and neuroplasticity
Mao, J. (1999) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00020-x · Cited by 273
Glutamate Receptors and Nociception: Implications for the Drug Treatment of Pain
Fundytus, M. E. (2001) · CNS Drugs · doi:10.2165/00023210-200115010-00004 · Cited by 250
Chartoff, E. H., & Connery, H. S. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00116 · Cited by 154
Metadata
- Authors
- Tokuyama, S., Wakabayashi, H., & Ho, I. K.
- Affiliations
- University of Mississippi Medical Center (US)
- Corresponding author
- Ho, Ing K.
- ORCID
- Tokuyama, Shogo
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 1996-01
- Volume
- 295
- Issue
- 2-3
- Pages
- 123-129
- ISSN
- 0014-2999 (ISSN-L)
- OpenAlex
- W2034348223
- Cited by
- 98
- References
- 39
- Citations by year
- 2026: 1 · 2023: 1 · 2021: 1 · 2020: 1 · 2019: 3 · 2018: 2 · 2017: 2 · 2016: 2 · 2015: 1 · 2014: 4 · 2013: 4 · 2012: 5
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- European Journal of Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (DA-05828)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Keywords
- opioid withdrawal, glutamate, NMDA receptor, morphine dependence, butorphanol, naloxone, MK-801, mu-opioid receptor, opioid use disorder
- MeSH terms
- Animals, Behavior, Animal, Male, Morphine, Naloxone, Narcotics, Substance Withdrawal Syndrome, Dizocilpine Maleate, Rats, Sprague-Dawley, Glutamic Acid, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Direct evidence for a role of glutamate in the expression of the opioid withdrawal syndrome. https://app.cochat.ai/papers/10.1016/0014-2999(95)00645-1
- The paper
- Tokuyama, S., Wakabayashi, H., & Ho, I. K. (1996). Direct evidence for a role of glutamate in the expression of the opioid withdrawal syndrome. European Journal of Pharmacology. https://doi.org/10.1016/0014-2999(95)00645-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.